| Lung disease with systemic sclerosis
Ofev vs Actemra
Side-by-side clinical, coverage, and cost comparison for lung disease with systemic sclerosis.Deep comparison between: Ofev vs Actemra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsActemra has a higher rate of injection site reactions vs Ofev based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Actemra but not Ofev, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ofev
Actemra
At A Glance
Oral
Twice daily
Kinase inhibitor
IV infusion or SC injection
Every 4 weeks (IV) or Every week to Every other week (SC)
IL-6 receptor antagonist
Indications
- Idiopathic Pulmonary Fibrosis
- PF-ILD-progressive fibrosing interstitial lung disease
- Lung disease with systemic sclerosis
- Rheumatoid Arthritis
- Giant Cell Arteritis
- Lung disease with systemic sclerosis
- Juvenile polyarthritis
- Systemic onset juvenile chronic arthritis
- Cytokine Release Syndrome
- COVID-19 Virus Disease
Dosing
Idiopathic Pulmonary Fibrosis, PF-ILD-progressive fibrosing interstitial lung disease, Lung disease with systemic sclerosis 150 mg orally twice daily approximately 12 hours apart with food; reduce to 100 mg twice daily in mild hepatic impairment (Child Pugh A).
Rheumatoid Arthritis IV: 4 mg/kg every 4 weeks, increase to 8 mg/kg every 4 weeks based on response; SC: 162 mg every other week (for <100 kg) or every week (for >=100 kg), increase to every week based on response.
Giant Cell Arteritis IV: 6 mg/kg every 4 weeks with tapering glucocorticoids; SC: 162 mg every week with tapering glucocorticoids (may use every other week based on clinical considerations).
Systemic Sclerosis-Associated Interstitial Lung Disease SC: 162 mg every week.
Polyarticular Juvenile Idiopathic Arthritis IV: 10 mg/kg every 4 weeks (<30 kg) or 8 mg/kg every 4 weeks (>=30 kg); SC: 162 mg every 3 weeks (<30 kg) or every 2 weeks (>=30 kg).
Systemic Juvenile Idiopathic Arthritis IV: 12 mg/kg every 2 weeks (<30 kg) or 8 mg/kg every 2 weeks (>=30 kg); SC: 162 mg every 2 weeks (<30 kg) or every week (>=30 kg).
Cytokine Release Syndrome IV: 12 mg/kg (<30 kg) or 8 mg/kg (>=30 kg) as single dose, alone or with corticosteroids; up to 3 additional doses at least 8 hours apart if no improvement.
COVID-19 IV: 12 mg/kg (<30 kg) or 8 mg/kg (>=30 kg) as single 60-minute infusion; one additional dose at least 8 hours later if clinical signs worsen or do not improve.
Contraindications
—
- Known hypersensitivity to tocilizumab
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decreased, hypertension
Serious Bronchitis, myocardial infarction, pneumonia, elevated liver enzymes, gastrointestinal disorders, arterial thromboembolic events, bleeding, gastrointestinal perforation
Postmarketing Thrombocytopenia, pancreatitis, drug-induced liver injury, posterior reversible encephalopathy syndrome, proteinuria, pruritus, rash, bleeding events
Most common (>=5%) Upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, injection site reactions (SC only).
Serious Serious infections (pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, bacterial arthritis), gastrointestinal perforations, hypersensitivity reactions including anaphylaxis.
Postmarketing Fatal anaphylaxis, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), pancreatitis, drug-induced liver injury, hepatitis, hepatic failure, jaundice, hypofibrinogenemia.
Pharmacology
Nintedanib is a small-molecule inhibitor of multiple receptor tyrosine kinases (PDGFR alpha/beta, FGFR 1-3, VEGFR 1-3, CSF1R, FLT-3) and non-receptor tyrosine kinases (Lck, Lyn, Src), blocking intracellular signaling cascades involved in fibrotic tissue remodeling in interstitial lung disease.
Tocilizumab is a humanized IgG1 kappa monoclonal antibody that binds to soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling involved in inflammatory and immune processes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ofev
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (11/12)
Actemra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Ofev
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (0/8) · Qty limit (7/8)
Actemra
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Ofev
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Actemra
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Pulmonary Fibrosis - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Actemra.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.